price feb usd
buy rate agil reect view compani opportun
growth margin expans capit deploy peer result
ep guid rais support out-performance
dgg acg busi oset shortfal lsag busi
support thesi
thing like
solid organ sale growth ep beat organ sale
growth came well estim consensu
double-digit growth dgg vs dbe acg
vs dbe partial oset lower-than-expect growth
double-digit sale growth dgg acg agil report robust sale
growth perform diagnost genom group dgg
agil crosslab group acg strength busi segment
broad-bas across custom end market geograph region
dgg organ sale growth prior year compar
propel good perform across compon
busi includ double-digit sale growth patholog next-
gen sequenc solut strength nucleic acid solut
divis nasd addit acg growth remain robust growth
acceler face prior year comp
fulli refresh gc product portfolio contributor lsag
rebound follow recent launch ga
chromatographi gc instrument agil fulli refresh gc
product portfolio expect contributor life scienc
appli group rebound meager growth pace
manag sound optimist premium mid-rang
drive instrument replac cycl compani
existing instal base manag expect
replac cycl occur faster pace intuvo gc launch
believ product cycl like support growth
curv catalyz acceler especi given agil high market
share gc
healthi oper margin expans adjust oper came well
forecast expand basi point y/i driven top-lin
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
leverag improv gross margin product enhanc
relat agil agil init oset tari-rel headwind
increas invest
thing cautiou
sale growth guid
like reflect
conservat organ sale growth guidanc rang
came consensus-lik estim believ reect
conservat particularli call sequenti deceler growth
despit meaning easier comparison compar apr-end
quarter vs jan-end quarter lsag busi expect
acceler inde manag note potenti upsid
outlook chemic energi busi
china busi deceler lsd pace underli trend remain
solid china busi deceler growth jan-end
quarter growth prior quarter manag attribut
meager perform came compani plan
dicult high-teen prior year compar incl comp chemic
 energi slower-than-anticip rebound china food
market follow govern ministri reorgan posit
side manag note underli trend remain solid particularli
biopharma environment exclud food china grew mid-
singl digit pace china busi expect acceler
guidanc contempl high-singl digit growth expect new
ga chromatographi product cycl target toward
 market help drive acceler
lsag growth deceler life scienc appli group
organ growth deceler prior quarter driven
primarili tough prior year compar slowdown china
food market relat recent china food ministri reorgan
lighter ga chromatographi gc demand custom held purchas
anticip recent new product launch gc
instrument mention modest neg impact
us govern shutdown expect busi rebound
comp lighten grow balanc year spur
new gc product cycl rebound china food market
price target
rais pt reect higher tool peer group
multipl price target agil reect enterpris valu use project
level debt cash ebitda ex option estim ttm
end multipl previous use
reect peer group multipl expans multipl in-lin life scienc
forecast ratio
period end incom expens expens incom share share ep dilut per sale oper cash flowoper cash cash revenu margin
period end equival st current equip intang asset cash lt sharehold equityaccount matur lt current liabil sh equiti minor februari
